Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4390-4395

  Bhat, Sunil V ^a   Peleg, Anton Y ^b   Lodise Jr , Thomas P ^c   Shutt, Kathleen A ^a   Capitano, Blair ^a   Potoski, Brian A ^a   Paterson, David L ^a,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CIPROFLOXACIN; CREATININE; LEVOFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSIS; DRUG DOSE REGIMEN; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; IN VIVO STUDY; KLEBSIELLA; KLEBSIELLA OXYTOCA; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; SERRATIA; SERRATIA MARCESCENS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36749011238     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01487-06     Document Type: Article

References (11)

1. Ambrose, P. G., S. M. Bhavnani, R. N. Jones, W. A. Craig, and M. N. Dudley. 2004. Use of pharmacokinetic-pharmacodynamic and Monte-Carlo simulation as decision support for the reevaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-138.
2. Bernard, G. R., J. L. Vincent, P. F. Laterre, S. P. LaRosa, J. F. Dhainaut, A. Lopez-Rodriguez, J. S. Steingrub, G. E. Garber, J. D. Helterbrand, E. W. Ely, and C. J. Fisher, Jr., for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709.
3. Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J. Quale. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435.
4. Clinical and Laboratory Standards Institute/NCCLS. 2001. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Knaus, W. A., D. P. Wagner, E. A. Draper, J. E. Zimmerman, M. Bergner, P. G. Bastos, C. A. Sirio, D. J. Murphy, T. Lotring, A. Damiano, et al. 1991. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100:1619-1636.
7. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
8. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
9. Peleg, A. Y., C. Franklin, J. M. Bell, and D. W. Spelman. 2005. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin. Infect. Dis. 41:1549-1556.
10. Reese, A. M., C. R. Frei, and D. S. Burgess. 2005. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms. Int. J. Antimicrob. Agents 26:114-119.
11. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-beta-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325.